Jasper Jan Brugts

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy
    Jasper J Brugts
    Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
    Curr Opin Cardiol 23:296-301. 2008
  2. ncbi Impaired sublingual microvascular perfusion during surgery with cardiopulmonary bypass: a pilot study
    Corstiaan A den Uil
    Erasmus MC Thoraxcenter, Rotterdam, The Netherlands
    J Thorac Cardiovasc Surg 136:129-34. 2008
  3. ncbi Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?
    Jasper J Brugts
    Department of Cardiology, Erasmus University Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Expert Rev Cardiovasc Ther 10:1001-9. 2012
  4. ncbi Right-to-left atrial shunting with normal intracardiac pressures following cardiac surgery: pathophysiology and management
    J J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, Rotterdam, The Netherlands
    J Card Surg 27:335-7. 2012
  5. ncbi The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
    J J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, 3015 GD, Rotterdam, Netherlands
    BMJ 338:b2376. 2009
  6. ncbi Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease
    Jasper J Brugts
    Department of Cardiology, Erasmus Medical Centers, Gravendijkwal 230, 3015CE Rotterdam, The Netherlands
    Expert Rev Cardiovasc Ther 7:345-60. 2009
  7. ncbi Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit
    Jasper J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, s Gravendijkwal 230, Rotterdam, The Netherlands
    Pharmacogenomics 11:1115-26. 2010
  8. ncbi The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials
    Jasper J Brugts
    Department of Cardiology, Erasmus University Medical Center, Thoraxcenter, s Gravendijkwal 230, 3015CE, Rotterdam, The Netherlands
    Eur Heart J 30:1385-94. 2009
  9. ncbi Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial)
    Jasper Jan Brugts
    Department of Cardiology, Interventional Cardiology and Clinical Epidemiology Unit, Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands
    Am J Cardiol 103:917-22. 2009
  10. ncbi A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals
    Jasper J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, Rotterdam, The Netherlands
    J Hypertens 29:509-19. 2011

Detail Information

Publications19

  1. ncbi Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy
    Jasper J Brugts
    Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
    Curr Opin Cardiol 23:296-301. 2008
    ..This review discusses several approaches to guide angiotensin-converting enzyme-inhibition therapy to more specific groups of patients that are most likely to benefit...
  2. ncbi Impaired sublingual microvascular perfusion during surgery with cardiopulmonary bypass: a pilot study
    Corstiaan A den Uil
    Erasmus MC Thoraxcenter, Rotterdam, The Netherlands
    J Thorac Cardiovasc Surg 136:129-34. 2008
    ..Microcirculatory blood flow alterations have been associated with impaired outcome. We investigated whether these alterations occurred before, during, and after coronary artery bypass grafting...
  3. ncbi Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?
    Jasper J Brugts
    Department of Cardiology, Erasmus University Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Expert Rev Cardiovasc Ther 10:1001-9. 2012
    ..The current review focuses on the recent developments in pharmacogenetic research in response to ACE inhibitors in patients with stable coronary artery disease...
  4. ncbi Right-to-left atrial shunting with normal intracardiac pressures following cardiac surgery: pathophysiology and management
    J J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, Rotterdam, The Netherlands
    J Card Surg 27:335-7. 2012
    ..We discuss the possible mechanisms and management of right-to-left atrial shunting through an atrial septum defect with normal intracardiac pressures following cardiac surgery...
  5. ncbi The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
    J J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, 3015 GD, Rotterdam, Netherlands
    BMJ 338:b2376. 2009
    ....
  6. ncbi Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease
    Jasper J Brugts
    Department of Cardiology, Erasmus Medical Centers, Gravendijkwal 230, 3015CE Rotterdam, The Netherlands
    Expert Rev Cardiovasc Ther 7:345-60. 2009
    ....
  7. ncbi Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit
    Jasper J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, s Gravendijkwal 230, Rotterdam, The Netherlands
    Pharmacogenomics 11:1115-26. 2010
    ..This article summarizes the recent findings of the PERGENE study and pharmacogenetic research of the treatment benefit of perindopril in stable coronary artery disease...
  8. ncbi The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials
    Jasper J Brugts
    Department of Cardiology, Erasmus University Medical Center, Thoraxcenter, s Gravendijkwal 230, 3015CE, Rotterdam, The Netherlands
    Eur Heart J 30:1385-94. 2009
    ....
  9. ncbi Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial)
    Jasper Jan Brugts
    Department of Cardiology, Interventional Cardiology and Clinical Epidemiology Unit, Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands
    Am J Cardiol 103:917-22. 2009
    ..In conclusion, moderate and severe periprocedural bleeding complications increased the risk of mortality and incident cardiovascular events after PCI...
  10. ncbi A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals
    Jasper J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, Rotterdam, The Netherlands
    J Hypertens 29:509-19. 2011
    ....
  11. ncbi The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease
    J J Brugts
    Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cardiovasc Drugs Ther 23:171-81. 2009
    ..Until now, pharmacogenetic research of the efficacy of ACE-inhibitor therapy in CAD patients is still in a preliminary stage...
  12. ncbi The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease
    J J Brugts
    Thoraxcenter, Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cardiology 112:303-12. 2009
    ..This review discusses several approaches to guide ACE inhibitor therapy in patients with coronary artery disease. In addition, the potential impact of pharmacogenetics regarding this particular topic is highlighted...
  13. ncbi Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study
    J J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Neth Heart J 20:24-32. 2012
    ..The main results of the PERGENE study show a pharmacogenetic profile related to the treatment benefit of perindopril identifying responders and non-responders to treatment...
  14. ncbi Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease
    Jasper Jan Brugts
    Department of Cardiology, Erasmus MC, Thoraxcenter, s Gravendijkwal 230, Rotterdam, The Netherlands
    Eur Heart J 31:1854-64. 2010
    ..However, these patients cannot be identified by clinical characteristics. We developed a genetic profile to predict the treatment benefit of ACE-inhibitors exist and to optimize therapy with ACE-inhibitors...
  15. ncbi The effects of intra-aortic balloon pump support on macrocirculation and tissue microcirculation in patients with cardiogenic shock
    Corstiaan A den Uil
    Thoraxcenter, Departments of Cardiology and Intensive Care Medicine, Erasmus Medical Center, s Gravendijkwal 230, Rotterdam NL 3015 CE, The Netherlands
    Cardiology 114:42-6. 2009
    ..It was the aim of this study to evaluate the effects of intra-aortic balloon pump (IABP) counterpulsation on sublingual microcirculation as a model for tissue perfusion...
  16. ncbi Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure
    Corstiaan A den Uil
    Erasmus Medical Center, Department of Cardiology and Intensive Care, NL 3015 CE Rotterdam, The Netherlands
    Eur J Heart Fail 11:386-90. 2009
    ..Impaired tissue perfusion is often observed in patients with acute heart failure. We tested whether low-dose nitroglycerin (NTG) improves microcirculatory perfusion in patients admitted for acute heart failure...
  17. ncbi The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial
    Jasper J Brugts
    Department of Cardiology, Thoraxcenter Erasmus Medical Center, Rotterdam, The Netherlands
    J Am Coll Cardiol 50:2148-55. 2007
    ..This study sought to examine whether the cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitor therapy by perindopril are modified by renal function in patients with stable coronary artery disease...
  18. ncbi Statin prescription in men and women at cardiovascular risk: to whom and when?
    Jasper J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, Rotterdam, The Netherlands
    Curr Opin Cardiol 25:484-9. 2010
    ..To review the recent evidence of the effectiveness of statin therapy in the primary prevention of cardiovascular disease in men and women without established cardiovascular disease (CVD)...
  19. ncbi Monitoring of the sublingual microcirculation in cardiac surgery using two-dimensional imaging
    Corstiaan A den Uil
    Anesthesiology 109:353-4; author reply 354-5. 2008